Atara Biotherapeutics logo

Atara Biotherapeutics (ATRA) Q1 2026 Earnings

ATRA·Reported May 12, 2026·Before market open

Atara Biotherapeutics reported Q1 2026 revenue of $516.0K (-99.5% YoY), missed analyst consensus of $2.9M by $2.4M. Diluted EPS came in at $-0.29, beat the $-0.33 consensus by $0.04.

Revenue
$516.0Kmissed by $2.4M
Consensus: $2.9M
Diluted EPS
$-0.29beat by $0.04
Consensus: $-0.33
SEC

SEC Filings

Earnings release8-K · 0001193125-26-219420
Quarterly report10-Q · 0001193125-26-219482

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about Atara Biotherapeutics's Q1 2026 earnings report.

Atara Biotherapeutics (ATRA) reported Q1 2026 earnings on May 12, 2026 before market open.

Atara Biotherapeutics reported revenue of $516.0K and diluted EPS of $-0.29 for Q1 2026.

Revenue missed the consensus estimate of $2.9M by $2.4M. EPS beat the consensus estimate of $-0.33 by $0.04.

Compared to the same quarter a year prior, revenue declined 99.5% from $98.1M a year earlier.

You can read the 8-K earnings release (0001193125-26-219420) and the 10-Q periodic report (0001193125-26-219482) directly on SEC EDGAR. The filing index links above go to sec.gov.